Asset Details
Do you wish to reserve the book?
A Novel Assay for Quantifying Gn-LRP1-Mediated Neutralizing Antibodies Against Severe Fever with Thrombocytopenia Syndrome Virus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Novel Assay for Quantifying Gn-LRP1-Mediated Neutralizing Antibodies Against Severe Fever with Thrombocytopenia Syndrome Virus
Do you wish to request the book?
A Novel Assay for Quantifying Gn-LRP1-Mediated Neutralizing Antibodies Against Severe Fever with Thrombocytopenia Syndrome Virus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Novel Assay for Quantifying Gn-LRP1-Mediated Neutralizing Antibodies Against Severe Fever with Thrombocytopenia Syndrome Virus
2026
Overview
Accurate and efficient determination of neutralizing antibody (nAb) is critical for assessing individual immune status of severe fever with thrombocytopenia syndrome (SFTS) and identifying key ecological reservoirs of the SFTS virus (SFTSV). However, conventional virus neutralization tests (cVNT) require live virus and are limited by their inability to support rapid, high-throughput screening. Here, we report a novel SFTSV virus neutralization test targeting the interaction between the SFTSV Gn protein and its receptor (LRP1). The test, which has been validated with SFTS patient plasma, achieves a sensitivity of 96.79% and a specificity of 100%. It also shows good correlation with cVNT, with an
value of 0.8902 in head-to-head comparison. This platform offers a safe, rapid, and high-throughput alternative for large-scale population screening and the real-time monitoring of immune responses in SFTS patients.
Publisher
Taylor & Francis Group
